Dynavax (NASDAQ:DVAX) Q2 results:
Total revenues: $2.7M (-67.5%); Heplisav-B sales: $2.4M (-67.5%).
Net loss: ($51.6M); loss/share: ($0.53).
Quick assets at quarter-end: $200.7M (+32.8%).
2020 expected milestones:
Final immunogenicity data on Heplisav-B in dialysis patients.
Completion of post-marketing safety follow-up on Heplisav-B.
Complete animal studies on pertussis vaccine CpG 1018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.